RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)
https://www.facingourrisk.org/research-clinical-trials/study/93/denosumab-and-mammographic-density-in-premenopausal-women-with-dense-breasts-trident
Clinicaltrials.gov identifier:
NCT04067726 (https://clinicaltrials.gov/show/NCT04067726)
Prevention
Study Contact Information:
About the Study
The purpose of this study is to evaluate if denosumab can reduce the breast density of premenopausal women who have dense breasts. Denosumab is an FDA-approved injectable medication that is used to treat osteoporosis and to prevent fractures in cancer patients with bone metastases. This study could help us identify novel ways to prevent breast cancer in younger women.
NOTE: This study is no longer enrolling people
This Study is Open To:
NOTE: This study is no longer enrolling people
This Study is Not Open To:
NOTE: This study is no longer enrolling people
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.